The frontal sinusitis treatment market focuses on managing inflammation or infection in the frontal sinuses caused by viral, bacterial, or fungal infections. Common treatments include antibiotics, decongestants, corticosteroids, and surgical interventions for severe cases. Recent advancements emphasize minimally invasive surgery such as endoscopic sinus surgery and drug-eluting stents, improving patient outcomes and recovery time. The market is influenced by the rising prevalence of sinusitis, advancements in diagnostic tools, and increasing awareness of effective treatments. The growing preference for non-invasive methods and innovative drug delivery systems, such as nasal sprays and topical medications, also drive market expansion. Recent developments include the introduction of biologics targeting chronic sinusitis and improved imaging technologies for precise diagnosis. Key players, including Pfizer Inc., Teva Pharmaceutical Industries Ltd., and GSK plc, are investing in R&D to cater to unmet medical needs, fostering competition and innovation within the market.
